Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone - Sorbonne Université
Journal Articles Drug and Alcohol Dependence Year : 2021

Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone

Abstract

Aim: To explore the factors determining the interest in extended-release buprenorphine (XR-BUP) injections among patients receiving opioid agonist treatment (OAT) in France. Methods: 366 patients receiving OAT for opioid use disorder, recruited in 66 French centers, were interviewed from 12/2018 to 05/2019. A structured questionnaire assessed their interest in XR-BUP using a [1-10] Likert scale. 'More' vs. 'less' interested groups were defined using the median score of interest, and their characteristics were explored using adjusted odds ratios (aORs) and 95 % confidence interval (95 %CI). Independent variables were as follows: sociodemographic characteristics, OAT-related features (e.g., type of OAT and prescriber, dosing, or duration of treatment), OAT representations, and personal objectives of treatment. Results: The median interest in XR-BUP was 7 (interquartile range: 3-9) out of 10. The participants who were 'more interested' (i.e. those scoring ≥7) showed no substantial difference in sociodemographic characteristics, relative to the 'less interested' participants. However, they more frequently reported forgetting to take their OAT (OR = 1.81; CI95 % = 1.06-3.10) or reported experiencing situations where taking their OAT was impractical (aOR = 1.69; CI95 % = 1.05-2.73). Their treatment objective was more focused on stopping illicit drugs (aOR = 1.67; 95 %CI = 1.02-2.70), reducing health risks (aOR = 3.57; 95 %CI = 1.67-7.69) and craving (aOR = 2.38; 95 %CI = 1.39-4.02) or improving family (aOR = 1.81; 95 %CI = 1.03-3.13) or professional (aOR = 2.22; 95 %CI = 1.43-3.85) recovery. Conclusions: In France, where the access to OAT is relatively unrestricted, the majority of participants were interested in XR-BUP formulations. Being interested was associated with treatment objectives focused on abstinence and recovery, and with experiencing constraints in taking a daily oral OAT.
Fichier principal
Vignette du fichier
1-s2.0-S0376871620306578-main.pdf (452.57 Ko) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-03280782 , version 1 (07-07-2021)

Identifiers

Cite

Benjamin Rolland, Benoit Trojak, Mikail Nourredine, Jérôme Bachellier, Mathieu Chappuy, et al.. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone. Drug and Alcohol Dependence, 2021, 220, pp.108492. ⟨10.1016/j.drugalcdep.2020.108492⟩. ⟨hal-03280782⟩
95 View
89 Download

Altmetric

Share

More